Evidence map›Paper›PMID 42394645›Full record

ReviewNeuro-oncology advances

Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives.

Désirée Sexauer, Elin S Gray, Helen Rizos, Pauline Zaenker, Aaron B Beasley

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Désirée SexauerCentre for Precision Health, Edith Cowan University, Perth, WA, Australia (D.S., E.S.G., P.Z., A.B.B.).ORCID https://orcid.org/0000-0003-0743-1607
Elin S GrayCentre for Precision Health, Edith Cowan University, Perth, WA, Australia (D.S., E.S.G., P.Z., A.B.B.).
Helen RizosFaculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
Pauline ZaenkerCentre for Precision Health, Edith Cowan University, Perth, WA, Australia (D.S., E.S.G., P.Z., A.B.B.).
Aaron B BeasleyCentre for Precision Health, Edith Cowan University, Perth, WA, Australia (D.S., E.S.G., P.Z., A.B.B.).ORCID https://orcid.org/0000-0001-5727-7463

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parenchymal brain metastases of solid malignancies remain a significant clinical challenge, as they are often detected at later symptomatic stages, which are typically associated with worse prognosis. Delayed detection limits treatment options and contributes to poor outcomes, while early detection is critical for improving patient outcomes and quality of life. In this comprehensive review, we investigated the potential use and challenges of blood-based biomarkers, including circulating tumor cells, cell-free DNA, noncoding RNAs, extracellular vesicles, proteins, and other immune-related biomarkers, for the early detection of parenchymal brain metastasis. The use of blood-based liquid biopsies offers a promising avenue for early detection and monitoring of brain metastases, potentially enabling timely intervention and tailored treatment regimes. Continued research and rigorous clinical validation are essential to fully harness the potential of blood-based biomarkers, which could transform clinical practice in oncology.

Indexed as

biomarkersdiagnosisintracranial metastasisliquid biopsyparenchymal brain metastasis

Identifiers

PMID42394645
PMCPMC13326755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.